[Implication of genetic polymorphism on neuropathic pain].
Various conditions are categorized to neuropathic pain, many of which are intractable requiring investigation using multiple approaches. Genetic polymorphism is one of such research fields that have provided much insight into conditions including postherpetic neuralgia, CRPS and postoperative pains. The research in genetic polymorphism is also expected to help expedite realization of the genomic personalized medicine in that selection and dosage of medication are determined according to each patient's specific set of requirements. In addition, the genetic polymorphism research effort in the field of drug discovery in areas such as metabolism, transporters and receptors is also expected to contribute to the clinical practice by expanding our knowledge in each of those areas.
Iseki
Masako
M
Department of Anesthesiology and Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431.
Sato-Takeda
Masako
M
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000493:pharmacokinetics; D002394:Catechol O-Methyltransferase / Q000235:genetics; D020918:Complex Regional Pain Syndromes / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D007206:Individuality; D008285:Major Histocompatibility Complex / Q000235:genetics; D009437:Neuralgia / Q000235:genetics*; D051474:Neuralgia, Postherpetic / Q000235:genetics; D010149:Postoperative Pain / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D000701:Analgesics, Opioid; D006680:HLA Antigens; D019389:Cytochrome P-450 CYP2D6; D002394:Catechol O-Methyltransferase